MTOR and melanoma: For example, in the elegant study of Hayes et al., through a gene-expression- and a gene-silencing-system, it was shown that receptor tyrosine kinases (RTK)-PI3K-AKT-mTOR pathway activity impairs sensitivity of melanoma cells to Palbociclib [55].